Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers
Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geria...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/14/4183 |
| _version_ | 1797446156999983104 |
|---|---|
| author | Dominik Safcak Sylvia Drazilova Jakub Gazda Igor Andrasina Svetlana Adamcova-Selcanova Lea Balazova Radovan Barila Michal Mego Marek Rac Lubomir Skladany Miroslav Zigrai Martin Janicko Peter Jarcuska |
| author_facet | Dominik Safcak Sylvia Drazilova Jakub Gazda Igor Andrasina Svetlana Adamcova-Selcanova Lea Balazova Radovan Barila Michal Mego Marek Rac Lubomir Skladany Miroslav Zigrai Martin Janicko Peter Jarcuska |
| author_sort | Dominik Safcak |
| collection | DOAJ |
| description | Background and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (<i>p</i> = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (<i>p</i> = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (<i>p</i> = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (<i>p</i> = 0.5), one and two comorbidities (<i>p</i> = 0.49), and three or more comorbidities (<i>p</i> = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted. |
| first_indexed | 2024-03-09T13:36:10Z |
| format | Article |
| id | doaj.art-91ab02f5672040ebabe9fc2ea178adf8 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T13:36:10Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-91ab02f5672040ebabe9fc2ea178adf82023-11-30T21:11:34ZengMDPI AGJournal of Clinical Medicine2077-03832022-07-011114418310.3390/jcm11144183Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak CentersDominik Safcak0Sylvia Drazilova1Jakub Gazda2Igor Andrasina3Svetlana Adamcova-Selcanova4Lea Balazova5Radovan Barila6Michal Mego7Marek Rac8Lubomir Skladany9Miroslav Zigrai10Martin Janicko11Peter Jarcuska12Department of Radiotherapy and Oncology, East Slovakia Institute of Oncology, Rastislavova 43, 041 91 Kosice, SlovakiaInternal Medicine Department, Hospital Poprad a.s., Banicka 803, 058 01 Poprad, Slovakia2nd Department of Internal Medicine, P. J. Safarik University, Faculty of Medicine and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, SlovakiaDepartment of Radiotherapy and Oncology, East Slovakia Institute of Oncology, Rastislavova 43, 041 91 Kosice, Slovakia2nd Department of Internal Medicine, HEGITO, F. D. Roosevelt University Hospital, Namestie L Svobodu 1, 975 17 Banska Bystrica, SlovakiaDepartment of Radiotherapy and Oncology, East Slovakia Institute of Oncology, Rastislavova 43, 041 91 Kosice, SlovakiaOncological Cluster, Stefan Kukura Hospital in Michalovce, Spitalska Ulica 2, 071 01 Michalovce, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Oncology Institute of Slovakia, Klenova 1, 833 10 Bratislava, SlovakiaDepartment of Internal Medicine, Teaching Hospital Nitra, Spitalska 6, 949 01 Nitra, Slovakia2nd Department of Internal Medicine, HEGITO, F. D. Roosevelt University Hospital, Namestie L Svobodu 1, 975 17 Banska Bystrica, Slovakia1st Department of Internal Medicine, Ladislav Derer University Hospital in Bratislava, Limbova 5, 833 05 Bratislava-Kramare, Slovakia2nd Department of Internal Medicine, P. J. Safarik University, Faculty of Medicine and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia2nd Department of Internal Medicine, P. J. Safarik University, Faculty of Medicine and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, SlovakiaBackground and Aims: Hepatocellular cancer (HCC) often occurs in geriatric patients. The aim of our study was to compare overall survival and progression-free survival between geriatric patients (>75 years) and patients younger than 75 years and to identify predictive factors of survival in geriatric patients with HCC. Material and Methods: We performed a retrospective analysis of patients with HCC diagnosed in Slovakia between 2010–2016. Cases (HCC patients ≥75 years) were matched to controls (HCC patients <74 years) based on the propensity score (gender, BCLC stage and the first-line treatment). Results: We included 148 patients (84 men, 57%) with HCC. There were no differences between cases and controls in the baseline characteristics. The overall survival in geriatric patients with HCC was comparable to younger controls (<i>p</i> = 0.42). The one-, two-, and three-year overall survival was 42% and 31%, 19% and 12%, and 12% and 9% in geriatric patients and controls, respectively (<i>p</i> = 0.2, 0.4, 0.8). Similarly, there was no difference in the one- and two-year progression-free survival: 28% and 18% vs. 10% and 7% in geriatric HCC patients and controls, respectively (<i>p</i> = 0.2, 1, -). There was no case–control difference between geriatric HCC patients and younger HCC controls in the overall survival in the subpopulation of patients with no known comorbidities (<i>p</i> = 0.5), one and two comorbidities (<i>p</i> = 0.49), and three or more comorbidities (<i>p</i> = 0.39). Log (CRP), log (NLR), log (PLR), and log (SII) were all associated with the three-year survival in geriatric HCC patients in simple logistic regression analyses. However, this time, only log (NLR) remained associated even after controlling for the age and BCLC confounding (OR 5.32, 95% CI 1.43–28.85). Conclusions. We found no differences in overall survival and progression-free survival between older and younger HCC patients. Parameters of subclinical inflammation predict prognosis in geriatric patients with HCC. A limitation of the study is small number of the treated patients; therefore, further investigation is warranted.https://www.mdpi.com/2077-0383/11/14/4183hepatocellular cancergeriatric patientsoverall survivalprogression-free survival |
| spellingShingle | Dominik Safcak Sylvia Drazilova Jakub Gazda Igor Andrasina Svetlana Adamcova-Selcanova Lea Balazova Radovan Barila Michal Mego Marek Rac Lubomir Skladany Miroslav Zigrai Martin Janicko Peter Jarcuska Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers Journal of Clinical Medicine hepatocellular cancer geriatric patients overall survival progression-free survival |
| title | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
| title_full | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
| title_fullStr | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
| title_full_unstemmed | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
| title_short | Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers |
| title_sort | inflammatory indexes as prognostic factors of survival in geriatric patients with hepatocellular carcinoma a case control study of eight slovak centers |
| topic | hepatocellular cancer geriatric patients overall survival progression-free survival |
| url | https://www.mdpi.com/2077-0383/11/14/4183 |
| work_keys_str_mv | AT dominiksafcak inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT sylviadrazilova inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT jakubgazda inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT igorandrasina inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT svetlanaadamcovaselcanova inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT leabalazova inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT radovanbarila inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT michalmego inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT marekrac inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT lubomirskladany inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT miroslavzigrai inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT martinjanicko inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters AT peterjarcuska inflammatoryindexesasprognosticfactorsofsurvivalingeriatricpatientswithhepatocellularcarcinomaacasecontrolstudyofeightslovakcenters |